Synapse - Stuart Lichtman

Results (19)

Germline landscape of ovarian cancer across age groups: Spotlight on elderly patients

Meeting Abstract

Sia, T. Y.; Moufarrij, S.; Zhou, Q.; Khurram, A.; Kemel, Y.; Iasonos, A.; Long Roche, K.; Stadler, Z. K.; Tew, W. P.; Lichtman, S. M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses

Journal Article

Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
Nature Medicine (2024)

Fulltext@MSK | Save

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

Journal Article

Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
Gynecologic Oncology (2023)

Fulltext@MSK | Save

A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)

Meeting Abstract

Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)

Meeting Abstract

Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Employing competing risks analysis in an aging population where many patients die from other causes

Journal Article

Flynn, J. R.; Bartlett, E. K.; Lichtman, S. M.; Panageas, K. S.
Journal of Geriatric Oncology (2022)

Fulltext@MSK | Save

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer

Journal Article

Manning-Geist, B. L.; Gordhandas, S. B.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; O'Cearbhaill, R. E.; Zamarin, D.; Lichtman, S. M.; Sabbatini, P. J.; more...
Gynecologic Oncology (2022)

Fulltext@MSK | Save

Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: An MSK Team Ovary phase II study

Journal Article

Zivanovic, O.; Chi, D. S.; Zhou, Q.; Iasonos, A.; Konner, J. A.; Makker, V.; Grisham, R. N.; Brown, A. K.; Nerenstone, S.; Diaz, J. P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

A randomized phase II trial of secondary cytoreductive surgery (SCS) plus /- carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with recurrent platinum-sensitive ovarian cancer (EOC)

Meeting Abstract

Zivanovic, O.; Chi, D.; Zhou, Q.; Iasonos, A.; Makker, V.; Grisham, R. N.; Konner, J. A.; Diaz, J. P.; Brown, A. K.; Langstraat, C. L.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma

Meeting Abstract

Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save